CompletedNot Applicable

The Effect of Electrostimulation and Compression Applications on Neuropathy Symptoms and Quality of Life in the Management of Chemotherapy-Induced Peripheral Neuropathy in Gastrointestinal System Cancer Patients Receiving Oxaliplatin-Based Treatment

Turkey (Türkiye)140 participantsStarted 2025-01-02

Plain-language summary

This research was conducted to evaluate the effect of electrostimulation and compression applications on the severity, number, and pain levels of neuropathy symptoms and the quality of life of patients with metastatic gastrointestinal cancer receiving oxaliplatin-based treatment in the management of chemotherapy-induced peripheral neuropathy. The study population consisted of patients with gastrointestinal cancer between 2025-2026 . Data collection tools were administered to patients who met the inclusion criteria and developed chemotherapy-induced peripheral neuropathy. Patients were then stratified by age and gender and assigned to "control group, electrostimulation group, compression group, and electrostimulation+compression group" using block randomization. Statistical power analysis determined the total number of participants in the study as 140 patients, with 35 patients in each group. Patients in the control group benefited from the clinic's standard procedures and received no intervention

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Being 18 years of age or older, * Having a diagnosis of metastatic gastrointestinal cancer (stomach, pancreas, colon, rectum), * Being scheduled to receive 6 cycles of chemotherapy, * Having received 1 cycle of oxaliplatin-based chemotherapy (FOLFOX and FOLFİRİNOX), * Not having a diagnosed mental disorder, * Not having skin problems in the areas where TENS and compression applications will be performed, * Having verbally and in writing approved the informed consent form after being informed and explained about the study. Exclusion Criteria: * Having previously received oxaliplatin-based treatment (monotherapy or combination), * Having a pacemaker, * Having a history of any skin sensitivity in the hands and feet, * Having received or currently receiving another neurotoxic chemotherapy agent other than oxaliplatin-based treatment, * Having developed peripheral neuropathy due to reasons other than chemotherapy \[tumor compression, nutritional deficiencies, infections, or major systemic disease (diabetes mellitus, etc.)\].

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

EORTC QLQ-C30 Quality of Life Scale

Timeframe: 10 weeks

Trial details

NCT IDNCT07409987

SponsorCumhuriyet University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-02-28

View on ClinicalTrials.gov More CIPN - Chemotherapy-Induced Peripheral Neuropathy trials